Announcing the Launch of the Life Sciences Workforce Collaborative — and a Preview of What’s Ahead

This week marks an important milestone for workforce development in the U.S. life sciences sector: the official launch of the Life Sciences Workforce Collaborative (LSWC). Formerly known as the Coalition of State Bioscience Institutes (CSBI), LSWC premiered at the 2025 BIO International Convention as a new national nonprofit—building on over a decade of state and regional leadership to expand industry-aligned solutions for talent development.

 

As the life sciences industry confronts evolving technologies, shifting economic headwinds, and persistent workforce challenges - including specialized talent needs, unmet demand for skilled biomanufacturers, positioning for future growth —LSWC offers a unified platform to scale solutions, support workforce readiness, and strengthen public-private partnerships across the country.

 

Just out of the gate, the new organization is pleased to announce a major insight-driven release later this month: the upcoming 2025 National Life Sciences Workforce Trends

 

Report, produced in partnership with TEConomy Partners and the NSF-funded InnovATEBIO National Biotech Education Center. Comprised of data from over 700 life science companies and 2.9 million job postings, the report will go live on June 24, 2025.

 

Why This Matters

The newly launched LSWC builds on more than a decade of trusted collaboration among 50+ state, regional and national life science organizations and workforce partners. Its mission: to align, advise, and accelerate talent development efforts across the entire life sciences talent pipeline—from middle school to mid-career--to build a competitive life sciences workforce.

Next week, the LSWC will launch the 2025 National Workforce Trends Report, the organization’s flagship effort. Now in its seventh edition, this biennial report draws on:

  • Responses from over 500 companies across 30 states and Puerto Rico
  • Interviews with over 200 life science executives
  • Analysis of 2.9 million unique job postings across the U.S. from the last four years

The report is the definitive source for understanding the real-world trends shaping hiring, upskilling, and STEM education engagement across the life sciences ecosystem. More to come next week.

 

What Comes Next

In the weeks ahead, we’ll be working with our partners to roll out media toolkits, schedule events, and activate coordinated campaigns to bring visibility to both the LSWC launch and the report.

 

We are deeply grateful to our investor-level supporters—AZBio/AZ Advances, BioNJ, BioUtah, California Life Sciences, Georgia Life Sciences/Institute, Colorado Bioscience Association/Institute, MichBio, NewYorkBIO/Institute, Ohio Life Sciences, Oregon Bioscience Association, SCbio, and Southern California Biomedical Council (SoCalBio)—LSWC partners and connectors, and to every organization that has shaped this initiative from the ground up.


Together, we are building a stronger, competitive, and future-ready workforce—one that ensures the U.S. remains the global leader in biotechnology, biomanufacturing, and life sciences innovation.

 

Stay tuned and learn how you can partner with us to advance the life sciences workforce.


Learn more at: www.LifeSciencesWorkforce.org
For media inquiries: connect@lifesciencesworkforce.org

GLS 2025 Year in Review

December 22, 2025
Dear Georgia Life Sciences Community, As we reflect on the past year, I want to extend my sincere thanks to our Georgia Life Sciences members for making it such an impactful one. Your engagement and leadership continue to move our industry forward and advance our shared strategic priorities— driving strong policy, expanding the talent pipeline, and creating intentional spaces for collaboration across Georgia’s life sciences ecosystem. Our Year in Review captures the progress we’ve made together across these priorities and highlights the collective impact our members are having statewide—from strengthening the workforce and supporting manufacturing growth to elevating Georgia’s position as a national life sciences leader. This progress is only possible because of the collaboration, commitment, and insight of our member community. 

Investing in America’s Biopharmaceutical Infrastructure Strengthens the Economy and Supports Union Workers

By Maria Thacker Goethe • December 20, 2025
The biopharmaceutical industry is growing America’s manufacturing and R&D capabilities to develop the next generation of treatments. A recent study from PILMA quantified the impact of the industry’s investment in American infrastructure on the economy and union workforce across 18 states from 2019-2024. The study found that across the 18 states included, the biopharmaceutical industry: Supported the American economy by investing $86.5B in R&D and manufacturing infrastructure and developing 1000+ construction projects at over 700 distinct facilities. Strengthened the American workforce by generating $2.6B in skilled union wages and providing $19M in support for union apprenticeships. The impact of the biopharmaceutical industry’s investment in American manufacturing and union jobs extends beyond direct benefits, spurring additional economic activity in the communities where workers live. This is known as the multiplier effect . On average, every $1 of new investment in a U.S. biopharmaceutical manufacturing facilities generates an additional $1.59 in further economic activity (2.59x times the initial investment value). The industry’s $86.5B investment in R&D and manufacturing infrastructure has a total economic impact of $224B. Check out this resource to learn more about how biopharmaceutical investment in American infrastructure supports America’s workers and communities. For more on how biopharmaceutical companies are investing in America’s future, visit innovation.org/america-investment .

Georgia Life Sciences Joins National Coalition Urging Congressional Action on Key Innovation Policies

December 10, 2025
Georgia Life Sciences has joined 43 state and regional life sciences organizations in signing a national Council of State Bioscience Associations (CSBA) letter calling on Congress to take immediate action on three bipartisan policy priorities that are essential to sustaining U.S. leadership in biomedical innovation and supporting patients nationwide. With Congress back in session and several critical programs at risk of expiring, the letter urges congressional leaders to advance the following provisions without delay: 1. Reauthorize the Rare Pediatric Disease Priority Review Voucher (PPRV) Program The PPRV program has been instrumental in incentivizing the development of therapies for children with rare and life-threatening conditions. Its lapse threatens to slow or halt research that families across the country are counting on. 2. Extend the SBIR/STTR Programs The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs provide crucial early-stage capital for emerging biotech and medtech companies—many of them in Georgia. Without reauthorization, hundreds of innovative small businesses face uncertainty, jeopardizing new therapies, diagnostics, and technologies in the pipeline, 3. Advance PBM Transparency Reforms Greater transparency and accountability within pharmacy benefit manager (PBM) practices are needed to ensure that savings reach patients and employers. Reforming PBM operations is essential to strengthening access and affordability across the healthcare system. A Unified Message from the Life Sciences Community The sign-on letter reflects broad, bipartisan alignment across the national life sciences ecosystem: researchers, entrepreneurs, investors, patient advocates, and state associations all share a common message— these programs underpin America’s global competitiveness and are vital to patients who rely on continued scientific progress. Georgia Life Sciences has shared the letter with members of Georgia’s congressional delegation and will continue engaging with policymakers to emphasize the importance of swift action.
MORE POSTS